Colonisation by extended-spectrum beta-lactamase-producing Klebsiella spp. in a paediatric intensive care unit

The Journal of Hospital Infection
S S S LevyJ B Correia

Abstract

A prospective cohort study was performed in order to study the incidence and risk factors for bacterial colonisation with extended-spectrum producing beta-lactamase (ESBL) Klebsiella spp. in children. The study took place in a paediatric intensive care unit (PICU) in Recife, Brazil over a five-month period in 2008. Rectal swabs were collected during the first 24h of admission and on the 2nd, 5th, 7th and 14th days of PICU stay. ESBL-producing strains of Klebsiella spp. were detected by Kirby-Bauer disc diffusion and confirmed by double disc synergy testing. A total of 186 children were enrolled with a median age of three years. The overall colonisation rate with ESBL-producing Klebsiella spp. was 14%, but 13 (7%) children were already colonised upon admission. The incidence density of colonisation during PICU admission was 14.2 per 1000 patient-days. On multivariable analysis, the use of third generation cephalosporins (P=0.008) was a risk factor for colonisation. Survival analysis revealed an increase in the accumulated risk of colonisation with an increase in length of stay in the PICU. The present study provides baseline information to guide improved practices in similar settings and direct future studies in relation to the ...Continue Reading

References

Feb 14, 2003·The New England Journal of Medicine·John P Burke
Jun 5, 2003·Pediatrics·Marlene R MillerChunliu Zhan
Jun 5, 2004·Clinics in Laboratory Medicine·Philip Toltzis
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Curtis J Donskey
Apr 28, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jerry Siegel

❮ Previous
Next ❯

Citations

May 29, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K GuyotE Bingen
Aug 24, 2012·Future Microbiology·Caitlin N Murphy, Steven Clegg
Jun 19, 2016·The Journal of Antimicrobial Chemotherapy·A HamprechtUNKNOWN DZIF-ATHOS Study Group
Aug 29, 2013·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Shefali K SharmaChhavi Sahney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.